G-1639A but Not C1173T<i>VKORC1</i>Gene Polymorphism Is Related to Ischemic Stroke and Its Various Risk Factors in Ukrainian Population

Dubovyk, Yevhen Ivanovych; Harbuzova, V. Yu.; Атаман, Олександр Васильович

doi:10.1155/2016/1298198

Cited by 11 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nonetheless, this limitation of our study is in direct relationship with its main strength, as our results stand as the first longitudinal study to assess the effect that VKORC1 and CYP4F2 polymorphisms have on boosting the risk of plaque development at 5 years. Until now, other studies have determined the role of this polymorphisms in a cross-sectional manner [12,30,35]. Therefore, the current study significantly advances the knowledge in the field of atherosclerotic plaque formation.…”

Section: Discussionmentioning

confidence: 78%

CYP4F2 and VKORC1 Polymorphisms Amplify the Risk of Carotid Plaque Formation

Vesa

Vlaicu

Văcăraș

et al. 2020

Genes

View full text Add to dashboard Cite

Introduction: Atherosclerosis represents the process by which fibrous plaques are formed in the arterial wall, increasing its rigidity with a subsequent decrease in blood flow which can lead to several cardiovascular events. Seeing as vitamin K antagonists are involved in the pathogenesis of atherosclerosis, we decided to investigate whether polymorphisms in genes that influence vitamin K metabolism might have an impact in modulating the risk of plaque formation. Patients and Methods: In the current study we included adult patients admitted in the Clinical Municipal Hospital of Cluj-Napoca without any carotid or femoral plaques clinically visible at the initial investigation, and a five year follow-up was subsequently performed. We recorded the following patient characteristics: age at inclusion, gender, area of living, smoking, presence of carotid and/or femoral plaques at five years, ischemic heart disease, arterial hypertension, atrial fibrillation, heart failure, diabetes mellitus, obesity, dyslipidemia, drug (oral anticoagulants, antihypertensives, hypolipidemic, anti-diabetic) use and status for the following gene polymorphisms: VKORC1 1639 G>A, CYP4F2 1347 G>T and GGCX 12970 C>G. Results: We observed that the major predictor of both carotid and femoral plaque formation is represented by ischemic cardiac disease. VKORC1 and CYP4F2 polymorphisms did not predict plaque formation, except for VKORC1 homozygous mutants. Nonetheless, both VKORC1 and CYP4F2 interacted with ischemic cardiac disease, increasing the risk of developing a carotid plaque, while only CYP4F2, but not VKORC1, interacted with ischemic cardiac disease to increase the risk of femoral plaque formation. Conclusions: We documented that CYP4F2 and VKORC1 polymorphisms boost the proinflammatory plaque environment (observed indirectly through the presence of ischemic heart disease), increasing the risk of plaque development.

show abstract

Section: Discussionmentioning

confidence: 78%

CYP4F2 and VKORC1 Polymorphisms Amplify the Risk of Carotid Plaque Formation

Vesa

Vlaicu

Văcăraș

et al. 2020

Genes

View full text Add to dashboard Cite

show abstract

“…The general characteristics of the study groups are summarized in Table 2 . Their detailed description was presented in our previous article [ 23 ].…”

Section: Resultsmentioning

confidence: 99%

Positive Association between EDN1 rs5370 (Lys198Asn) Polymorphism and Large Artery Stroke in a Ukrainian Population

et al. 2018

Self Cite

View full text Add to dashboard Cite

There are a lot of convincing evidences about the involvement of endothelin pathway proteins in the pathogenesis of atherosclerosis and its fatal complications. In this study, the analysis of a possible association between EDN1 rs5370 and EDNRA rs5335 gene polymorphisms and the risk of large artery stroke (LAS) in a Ukrainian population was conducted. 200 LAS patients and 200 unrelated controls were enrolled in a case-control study. The polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP) was used for SNP genotyping. Our results revealed that EDN1 rs5370 polymorphism was associated with LAS development both before and after adjustment for atherosclerosis risk factors (sex, age, body mass index, arterial hypertension, type 2 diabetes mellitus, and smoking). The risk for a LAS incident in rs5370-T allele carriers was 1.6 times higher (CI = 1.066–2.403; P = 0.020) than in subjects with the GG genotype. No link between EDNRA rs5335 and LAS risk in a Ukrainian population was found. The present study indicated that EDN1 rs5370, but not EDNRA rs5335, can be the strong genetic predictor for LAS development in a Ukrainian population.

show abstract

“…The presence of the rs9923231 polymorphism seriously impaired the function of VKORC1 and led to resistance to warfarin. 15,16 Patients with the rs9923231 G allele may have a different dosage versus effect relationship than wild-type patients. Therefore, these patients need a larger initiation dosage to affect anticoagulant time, and they may also need a larger dosage adjustment than the current routine dosage adjustment to bring an abnormal INR value into the target range.…”

Section: Discussionmentioning

confidence: 99%

The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin

Jiang

Liu

Wang

et al. 2017

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Differences in warfarin maintenance dosages based on the presence of polymorphisms in VKORC1, CYP2C9, CYP4F2, and ORM1 can be determined through dosage adjustment according to routine guidelines. Little is known about whether routine therapy could provide consensus anticoagulation control for patients with different genotypes. This study was carried out to compare anticoagulant control in patients with different genotypes. Six hundred seventy patients using warfarin according to Chinese guidelines were enrolled. Warfarin dosages and monitored international normalized ratios (INRs) were recorded. Genotypes of VKORC1 rs9923231, CYP4F2 rs2108622, CYP2C9 rs1057910, and ORM1 rs17650 polymorphisms were determined. Warfarin dosages and INR were compared between genotypes. Patients with the AGCC*F*F*1*1 polymorphism took longer than patients with the AACC*F*F*1*1 polymorphism (20 vs 5 days, P < .001) to achieve the targeted INR range. The INR values of patients with AACC*F*F*1*3 were unstable and did not enter the stable state control phase until after 35 days. The peak INR of patients with the AACC*F*F*1*3 polymorphism was exceedingly high, with some values exceeding the control range limit of 3.0. Patients with the AACC*F*S*1*1 or AACT*F*F*1*1 polymorphisms exhibited similar INR values as the patients with the AACC*F*F*1*1 polymorphism. This study found that routine medication with warfarin provides significantly different levels of anticoagulant control between patients with wild-type genotypes and patients with heterozygous polymorphism genotypes of VKORC1 rs9923231 or CYP2C9 rs1057910. Patients with heterozygous polymorphism genotypes of VKORC1 or CYP2C9 require genotype-directed therapy with warfarin to increase efficacy and safety in anticoagulant treatment.

show abstract

G-1639A but Not C1173TVKORC1Gene Polymorphism Is Related to Ischemic Stroke and Its Various Risk Factors in Ukrainian Population

Cited by 11 publications

References 27 publications

CYP4F2 and VKORC1 Polymorphisms Amplify the Risk of Carotid Plaque Formation

CYP4F2 and VKORC1 Polymorphisms Amplify the Risk of Carotid Plaque Formation

Positive Association between EDN1 rs5370 (Lys198Asn) Polymorphism and Large Artery Stroke in a Ukrainian Population

The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin

Contact Info

Product

Resources

About